PMID- 30572481
OWN - NLM
STAT- MEDLINE
DCOM- 20190104
LR  - 20200225
IS  - 1536-5964 (Electronic)
IS  - 0025-7974 (Print)
IS  - 0025-7974 (Linking)
VI  - 97
IP  - 51
DP  - 2018 Dec
TI  - Impact of metformin use on survival outcomes in non-small cell lung cancer 
      treated with platinum.
PG  - e13652
LID - 10.1097/MD.0000000000013652 [doi]
LID - e13652
AB  - Preclinical evidence suggests that metformin, a widely used antidiabetic drug, 
      may have a sensitizing effect on platinum. The purpose of this study was to 
      evaluate the survival outcomes for non-small cell lung cancer (NSCLC) patients 
      with type 2 diabetes mellitus (T2DM) using metformin during platinum-based 
      chemotherapy.The clinicopathological parameters and survival data of 75 NSCLC 
      patients with T2DM from January 2008 to December 2011 were collected and analyzed 
      retrospectively. Patients were divided into 2 groups: metformin exposure group 
      (n = 27) and non-metformin group (patients using other hypoglycemic agents or no 
      drug for controlling n = 48). Univariate and multivariate analyses were performed 
      to assess the association of metformin usage with overall survival (OS).Mean 
      follow-up time was 58.7 months. The mean survival time was 36.74 months in the 
      metformin group and 40.21 months in the non-metformin group. There was no 
      significant difference in survival time between the 2 groups (P = .661). After 
      adjusting gender, age, smoking status, tumor stage, tumor histology, and 
      differentiation, multivariate analysis showed that metformin was not associated 
      with the OS in NSCLC patients treated with concurrent platinum-based chemotherapy 
      (hazard ratio: 1.071, 95% confidence interval: 0.577-1.986, P = .828).Our results 
      indicated that metformin exposure had no significant effect on OS in NSCLC 
      patients treated with platinum-based chemotherapy. Further studies are warranted 
      to evaluate whether metformin could affect the survival of NSCLC patients treated 
      with platinum-based chemotherapy.
FAU - Wen-Xiu, Xin
AU  - Wen-Xiu X
AD  - Laboratory of Clinical Pharmacy.
AD  - Key Laboratory of Head and Neck Translational Research of Zhejiang Province 
      Zhejiang Cancer Hospital, Hangzhou, P.R. China.
FAU - Xiao-Wei, Zheng
AU  - Xiao-Wei Z
AD  - Laboratory of Clinical Pharmacy.
FAU - Hai-Ying, Ding
AU  - Hai-Ying D
AD  - Laboratory of Clinical Pharmacy.
FAU - Ying-Hui, Tong
AU  - Ying-Hui T
AD  - Laboratory of Clinical Pharmacy.
FAU - Si-Si, Kong
AU  - Si-Si K
AD  - Laboratory of Clinical Pharmacy.
FAU - Xiao-Fang, Zhou
AU  - Xiao-Fang Z
AD  - Laboratory of Clinical Pharmacy.
FAU - Huang, Ping
AU  - Huang P
AD  - Laboratory of Clinical Pharmacy.
AD  - Key Laboratory of Head and Neck Translational Research of Zhejiang Province 
      Zhejiang Cancer Hospital, Hangzhou, P.R. China.
LA  - eng
PT  - Evaluation Study
PT  - Journal Article
PL  - United States
TA  - Medicine (Baltimore)
JT  - Medicine
JID - 2985248R
RN  - 0 (Antineoplastic Agents)
RN  - 0 (Hypoglycemic Agents)
RN  - 0 (Platinum Compounds)
RN  - 9100L32L2N (Metformin)
SB  - IM
MH  - Aged
MH  - Antineoplastic Agents/therapeutic use
MH  - Carcinoma, Non-Small-Cell Lung/drug therapy/etiology/*mortality
MH  - Diabetes Mellitus, Type 2/complications/*drug therapy/mortality
MH  - Female
MH  - Follow-Up Studies
MH  - Humans
MH  - Hypoglycemic Agents/*therapeutic use
MH  - Lung Neoplasms/drug therapy/etiology/*mortality
MH  - Male
MH  - Metformin/*therapeutic use
MH  - Middle Aged
MH  - Multivariate Analysis
MH  - Platinum Compounds/*therapeutic use
MH  - Proportional Hazards Models
MH  - Retrospective Studies
MH  - Survival Rate
MH  - Treatment Outcome
PMC - PMC6320173
COIS- The authors have no conflicts of interest to disclose.
EDAT- 2018/12/24 06:00
MHDA- 2019/01/05 06:00
PMCR- 2018/12/21
CRDT- 2018/12/22 06:00
PHST- 2018/12/22 06:00 [entrez]
PHST- 2018/12/24 06:00 [pubmed]
PHST- 2019/01/05 06:00 [medline]
PHST- 2018/12/21 00:00 [pmc-release]
AID - 00005792-201812210-00060 [pii]
AID - MD-D-18-05263 [pii]
AID - 10.1097/MD.0000000000013652 [doi]
PST - ppublish
SO  - Medicine (Baltimore). 2018 Dec;97(51):e13652. doi: 10.1097/MD.0000000000013652.